Nextstellis®
Oral Contraception
MarketedCommercial Growth
Key Facts
About Mayne Pharma Group
Mayne Pharma is a specialty pharmaceutical company with a mission to improve patient access to life-enhancing medications through a dual-pillar strategy of proprietary product commercialization and contract services. The company has achieved significant commercial traction in the US with its Women's Health and Dermatology portfolios, supported by a deep expertise in complex oral and topical drug delivery systems. Its current strategic focus is on executing growth within its core therapeutic areas, managing the recently announced acquisition scheme with Cosette Pharmaceuticals, and optimizing its capital allocation to drive shareholder value.
View full company profileTherapeutic Areas
Other Oral Contraception Drugs
| Drug | Company | Phase |
|---|---|---|
| Aubra EQ | Afaxys | Approved |
| Chateal EQ | Afaxys | Approved |
| Cyred EQ | Afaxys | Approved |
| Jasmiel | Afaxys | Approved |
| Tarina 24 Fe | Afaxys | Approved |
| Tarina Fe 1/20 EQ | Afaxys | Approved |
| Tri-VyLibra | Afaxys | Approved |
| Tri-VyLibra Lo | Afaxys | Approved |
| VyLibra | Afaxys | Approved |